The effect of oestrogen replacement therapy on urinary tract dysfunction and urogenital collagen structure in postmenopausal women with stress incontinence

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN06344732

Enrollment

Registered

2004-01-23

Start date

1995-08-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological and genital diseases: Incontinence Urological and Genital Diseases Incontinence

Interventions

1. Six months therapy with oestradiol valerate 2 mg daily 2. Placebo

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Post-menopausal women with genuine stress incontinence, not taking hormone replacement therapy

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Assessment prior to treatment and upon study completion with the SF-36 health status questionnaire, the Bristol Female Lower Urinary Tract Symptoms questionnaire, a one week urinary diary, one hour perineal pad test, cystometry and urethral profilometry.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026